All In Biotech

Drug Trial Radar · NCT07858565

Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder

Study of Quality of Life, Safety and Compliance During Treatment of Schizophrenia or Bipolar Affective Disorder, in Patients Using the Drug Kvepin® (Quetiapine) as Monotherapy or Combination Therapy With Other Antipsychotics (Ispitivanje Kvalitete života, Sigurnosti i Saradljivosti u Toku liječenja Shizofrenije Ili Bipolarnog Afektivnog poremećaja, Kod Pacijenata Koji Koriste Lijek Kvepin® (Kvetiapin) Kao Monoterapiju Ili Kombinovanu Terapiju sa Drugim Antipsihoticima)

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Oct 30, 2025

Primary completion

Apr 2027

Study completion May 2027

Sponsor

Lead sponsor
Bosnalijek D.DIndustry
Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in combination with another antipsychotic/antipsychotics. The main outcome measures are: * quality of life using the World Health Organization Quality of Life questionnaire (WHOQOL) * safety through the monitoring of the incidence of possible adverse drug events by the researcher, with the assessment of the association between the administration of the drug and the occurrence of an adverse reaction * therapy adherence using the Medication Adherence Rating Scale (MARS). The subjects will be divided into two groups: 1. Newly diagnosed patients with a diagnosis of schizophrenia or bipolar affective disorder whose individual therapeutic approach, based on the clinical assessment of the research physician, includes one of the following therapies: 1. monotherapy with the drug quetiapine 2. combined antipsychotic therapy with quetiapine and aripiprazole 3. combined antipsychotic therapy with quetiapine and haloperidol 2. Patients with a diagnosis of schizophrenia or bipolar affective disorder who are on therapy with one of the antipsychotics (aripiprazole or haloperidol), and who, based on the clinical assessment of the investigator, require adjunctive quetiapine therapy. This group will include two subgroups of patients: 1. combined antipsychotic therapy with quetiapine and aripiprazole 2. combined antipsychotic therapy with quetiapine and haloperidol Recruitment of subjects will be carried out by physicians/researchers based on the patient's history and diagnosis. The diagnosis of schizophrenia or bipolar affective disorder will be based on the standard diagnostic criteria in medical practice (validated measurement scales in psychiatry - Young's Mania Scale, Beck Depression Scale and PANNS Schizophrenia Scale). Patients will have four visits to physician/researcher: 1. First visit - baseline at which patient will be included in the study 2. Second visit - 4 months after the baseline 3. Third visit - 8 months after the baseline 4. Fourth visit - 12 months after the baseline

Conditions

  • Schizophrenia
  • Bipolar Affective Disorder

Interventions

  • Quetiapine (drug)Drug

    Monotherapy with the drug quetiapine

  • quetiapine + aripiprazoleDrug

    Combined antipsychotic therapy with quetiapine and aripiprazole

  • quetiapine + haloperidolDrug

    Combined antipsychotic therapy with quetiapine and haloperidol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measurement of quality of life using the World Health Organization Quality of Life questionnaire (WHOQOL)-BREFTime frame: 12 months from inclusion into the study (baseline)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinic of Psychiatry, University Clinical Center of Sarajevo

    Sarajevo, Bosnia and Herzegovina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.